Therefore, there is an urgent need for new tools to accurately evaluate the HER2 expression status of patients with breast cancer in order to more quickly and accurately develop individualized treatment plans and to improve the prognosis of patients with breast cancer. Here, ERBB2 is linked to breast carcinoma.